December 30, 2018 – Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin and often presents as or evolves into acute leukemia. The disease is more common in men than women and in patients 60 years and older. Until now, the standard of care for BPDCN has been intensive chemotherapy followed by bone marrow transplantation. However, many patients with BPDCN were unable to tolerate this intensive therapy, and therefore an urgent need for alternative treatment options for this rare condition existed for quite some time already.
Capillary leak syndrome; life-threading and potentially fatal.
This may change now. On December 21, 2018, the American Food and Drug Administration (FDA) just approved Tagraxofusp-erzs (Elzonris) for the targeted treatment of BPDCN in adults and in pediatric patients, two years of age and older. Tagraxofusp-erzs is a interleukin-3 receptor (CD123) directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123- expressing cells.
The efficacy of Tagraxofusp-erzs (Elzonris) was studied in two cohorts of patients in a single-arm clinical trial. The first trial cohort enrolled 13 patients with untreated BPDCN, and seven patients (54%) achieved complete remission (CR) or CR with a skin abnormality not indicative of active disease (CRc). The second cohort included 15 patients with relapsed or refractory BPDCN. One patient achieved CR and one patient achieved CRc.
Common side effects reported by patients in clinical trials were capillary leak syndrome (fluid and proteins leaking out of tiny blood vessels into surrounding tissues), nausea, fatigue, swelling of legs and hands (peripheral edema), fever (pyrexia), chills and weight increase. Most common laboratory abnormalities were decreases in lymphocytes, albumin, platelets, hemoglobin and calcium, and increases in glucose and liver enzymes (ALT and AST). Health care providers are advised to monitor liver enzyme levels and for signs of intolerance to the infusion. Women who are pregnant or breastfeeding should not take Tagraxofusp-erzs (Elzonris) because it may cause harm to a developing fetus or newborn baby. The labeling for Tagraxofusp-erzs (Elzonris) contains a Black boxed Warning to alert health care professionals and patients about the increased risk of capillary leak syndrome which may be life-threatening or fatal to patients in treatment.
In terms of patient safety, both physicians and patients need to exert extreme caution. Tagraxofusp-erzs (Elzonris) was approved based on clinical data obtained from a very minimal number of patients (28 patients from two cohorts only) and yet, the impressive collection of adverse effects, as indicate above, have been noted. And, most troublesome, one of the effects, namely capillary leak syndrome, can truly be life-threatening and fatal for affected patients.
If at any time you would like to know more about BPDCN, please follow this video:
About the Author
Ph.D.; Professor in Pharmacology and Toxicology.
Senior expert in theragenomic and personalized medicine and individualized drug safety.
Senior expert in pharmaco- and toxicogenetics.
Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
No comments yet
Report Content to Admin
Reason for Report:
ERROR: Please select Reason for Report.ERROR: Please fill Reason for Report.
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders. Researchers collected data on survival, hospitalization rates, metabolic crises, liver transplantation, and cognitive outcome. This represents the […]
In a study by The Wistar Institute and collaborators, a rare, African-specific variant of the TP53 gene called P47S causes iron accumulation in macrophages and other cell types and is associated with poorer response to bacterial infections, along with markers of iron overload in African Americans. Macrophage iron accumulation disrupts their function, resulting in more […]
Over the last two decades, the health sciences have been transformed by genomics, which has provided insights into genetic risk factors for human disease. While powerful, the genomics revolution has also revealed the limits of genetic determinants, which account for only a fraction of total disease risk. A new article in the journal Science argues […]
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types—the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors—or vehicles—that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic […]
A new study published in Seizure gives insight into the short-term outcome of patients treated for status epilepticus in Kuopio University Hospital in Finland. The researchers found a 9% risk of death and a 32% risk of functional loss at one month after status epilepticus. The patient's risk of death could be predicted relatively reliably […]
New research done at the University of the Witwatersrand in Johannesburg, South Africa, and Huazhang University of Science and Technology in Wuhan, China, has exciting implications for secure data transfer across optical fiber networks.
Iron deficiency is a critical situation for plants, which respond using specific genetic programmes. Biologists from Heinrich Heine University Düsseldorf (HHU) and Michigan State University (MSU) used artificial intelligence methods to examine how to predict regulatory genetic sequences. They have now published the findings from their joint research work in the journal Plant Physiology.
A sustained state of vigilance will generate a different type of memory than a momentary startle, and these differences are linked to distinct signaling molecules in the brains of mice. Researchers at the RIKEN Center for Brain Science (CBS) have visualized these dynamics in the living mouse brain for the first time, observing two molecular […]
A new study in Frontiers in Neuroscience used virtual reality to determine how people plan their movements by 'seeing' gravity using visual cues in the landscape around them, rather than 'feeling it' through changes in weight and balance.
thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide
Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,